CO5650225A2 - Composicion farmaceutica que comprende analogos de somatostatina ciclicos - Google Patents
Composicion farmaceutica que comprende analogos de somatostatina ciclicosInfo
- Publication number
- CO5650225A2 CO5650225A2 CO05130258A CO05130258A CO5650225A2 CO 5650225 A2 CO5650225 A2 CO 5650225A2 CO 05130258 A CO05130258 A CO 05130258A CO 05130258 A CO05130258 A CO 05130258A CO 5650225 A2 CO5650225 A2 CO 5650225A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- hsst5
- hsst3
- formula iii
- complexing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
Abstract
3.- Un compuesto de la Fórmula III, por ejemplo el Compuesto B, o una sal farmacéuticamente aceptable o complejo del mismo, para utilizarse en la preparación de una composición farmacéutica para utilizarse en cualquier método como se define en 2 anterior.Un compuesto conjugado de la Fórmula III, por ejemplo el Compuesto B, o una sal farmacéuticamente aceptable del mismo, es útil ya sea como un agente de formación de imágenes, por ejemplo de visualización de tejidos y células positivos para el receptor de hsst3 y/o hsst5, por ejemplo tumores y metástasis positivos para el receptor de hsst3 y/o hsst5, trastornos inflamatorios o autoinmunes que exhiban a los receptores de somatostatina, tuberculosis o rechazo de órgano después de trasplante, al formar complejo con un elemento detectable, por ejemplo un núclido emisor de ? ó de positrones, un ion de metal fluorescente, o un ion paramagnético, por ejemplo 111In, 181Tb, 177Lu, 86Y, 68Ga, Eu3+, Gd3+, Fe3+, Mn2+, ó Cr2+, o como un producto radiofarmacéutico para el tratamiento in vivo de tumores y metástasis positivos para el receptor de hsst3 y/o hsst5, artritis reumatoide y condiciones de inflamación severas al formar complejo con un núclido emisor de a ó ß, o un núclido con cascadas de Auger-e-, por ejemplo 90Y, 161Tb, 177Lu, 211At, 213BI, ó 201TI, como se indica mediante las pruebas convencionales.En particular, se observa que el Compuesto A conjugado se enlaza con los receptores de somatostatina con valores pKi de aproximadamente 8 a 10. El compuesto del Ejemplo 10, formando complejo, por ejemplo, con 111In, 88Y, 90Y, ó 177Lu, se enlaza en el intervalo de nM con los sub-tipos sst respectivos, de acuerdo con el perfil de enlace del Compuesto B.La afinidad de un compuesto conjugado de la Fórmula III, por ejemplo el Compuesto B conjugado, y sus complejos para los receptores de hsst3 y/o hsst5, también se puede demostrar mediante prueba in vivo, de acuerdo con los métodos de prueba convencionales, por ejemplo como se dan a conocer en la Patente Británica Número GB-A-2,225,579. Por ejemplo, el compuesto del Ejemplo 10 formando complejo, por ejemplo, con 111In, 68Y, 90Y, ó 177Lu, da una acumulación de tumor significativa 4 horas después de su inyección en ratones o ratas que lleven un tumor pancreático exocrino que exprese a los receptores de hsst5.Después de la administración de un compuesto conjugado de la Fórmula III, por ejemplo el Compuesto B conjugado, en una forma de complejo, por ejemplo radiomarcado con 111In, 177Lu, 86Y, ó 181Tb, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314695A GB0314695D0 (en) | 2003-06-24 | 2003-06-24 | Organic compounds |
| GB0325388A GB0325388D0 (en) | 2003-10-30 | 2003-10-30 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5650225A2 true CO5650225A2 (es) | 2006-06-30 |
Family
ID=33554159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05130258A CO5650225A2 (es) | 2003-06-24 | 2005-12-27 | Composicion farmaceutica que comprende analogos de somatostatina ciclicos |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20070093412A1 (es) |
| EP (1) | EP1648934B1 (es) |
| JP (1) | JP4746541B2 (es) |
| KR (1) | KR101124136B1 (es) |
| AR (1) | AR044852A1 (es) |
| AT (1) | ATE438659T1 (es) |
| AU (1) | AU2004251866B2 (es) |
| BR (1) | BRPI0411820B8 (es) |
| CA (1) | CA2529449C (es) |
| CL (1) | CL2004001579A1 (es) |
| CO (1) | CO5650225A2 (es) |
| CY (1) | CY1109444T1 (es) |
| DE (1) | DE602004022420D1 (es) |
| DK (1) | DK1648934T3 (es) |
| EC (1) | ECSP056237A (es) |
| ES (1) | ES2328144T3 (es) |
| HK (1) | HK1089776A1 (es) |
| HR (1) | HRP20090571T1 (es) |
| IL (1) | IL172329A (es) |
| IS (1) | IS2705B (es) |
| MA (1) | MA27862A1 (es) |
| MX (1) | MXPA05013821A (es) |
| MY (1) | MY145375A (es) |
| NO (1) | NO330706B1 (es) |
| NZ (1) | NZ544157A (es) |
| PE (1) | PE20050285A1 (es) |
| PL (1) | PL1648934T3 (es) |
| PT (1) | PT1648934E (es) |
| RU (1) | RU2355418C2 (es) |
| SI (1) | SI1648934T1 (es) |
| TW (1) | TWI361194B (es) |
| WO (1) | WO2005000893A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008329826B2 (en) | 2007-11-28 | 2013-01-17 | Novartis Ag | Use of somatostatin analogs in meningioma |
| CN101883785B (zh) * | 2007-12-03 | 2014-01-15 | 意大利法尔马科有限公司 | 新的非选择性生长抑素类似物 |
| FR2942227B1 (fr) * | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| CA2925651A1 (en) * | 2013-09-30 | 2015-04-02 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| CN104447962B (zh) * | 2014-12-29 | 2018-07-17 | 成都圣诺生物科技股份有限公司 | 一种合成帕瑞肽的方法 |
| GB201816637D0 (en) | 2018-10-12 | 2018-11-28 | Heptares Therapeutics Ltd | Selective somatostatin receptor agonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328214A (en) * | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| EP0083305B1 (de) * | 1981-12-24 | 1985-07-10 | Ciba-Geigy Ag | Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung |
| US4612366A (en) * | 1985-06-17 | 1986-09-16 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| JPH02111A (ja) * | 1987-08-03 | 1990-01-05 | Toyo Jozo Co Ltd | 経鼻投与用生理活性ペプチド製剤 |
| JP2641755B2 (ja) | 1988-01-29 | 1997-08-20 | 住友製薬株式会社 | コントロールリリース製剤 |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| EP1099707A3 (en) | 1993-06-23 | 2002-01-09 | Diatide, Inc. | Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| ES2167189B1 (es) | 1999-12-17 | 2003-04-01 | Lipotec Sa | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| JP5721624B2 (ja) * | 2008-07-08 | 2015-05-20 | ノバルティス アーゲー | 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用 |
-
2004
- 2004-06-22 AR ARP040102163A patent/AR044852A1/es not_active Application Discontinuation
- 2004-06-22 PE PE2004000610A patent/PE20050285A1/es not_active Application Discontinuation
- 2004-06-23 AT AT04740213T patent/ATE438659T1/de active
- 2004-06-23 RU RU2006101720/15A patent/RU2355418C2/ru active Protection Beyond IP Right Term
- 2004-06-23 EP EP04740213A patent/EP1648934B1/en not_active Expired - Lifetime
- 2004-06-23 WO PCT/EP2004/006794 patent/WO2005000893A2/en active Search and Examination
- 2004-06-23 SI SI200431269T patent/SI1648934T1/sl unknown
- 2004-06-23 KR KR1020057024845A patent/KR101124136B1/ko active IP Right Grant
- 2004-06-23 MY MYPI20042450A patent/MY145375A/en unknown
- 2004-06-23 CL CL200401579A patent/CL2004001579A1/es unknown
- 2004-06-23 DE DE602004022420T patent/DE602004022420D1/de not_active Expired - Lifetime
- 2004-06-23 PL PL04740213T patent/PL1648934T3/pl unknown
- 2004-06-23 PT PT04740213T patent/PT1648934E/pt unknown
- 2004-06-23 CA CA2529449A patent/CA2529449C/en not_active Expired - Lifetime
- 2004-06-23 TW TW093118140A patent/TWI361194B/zh not_active IP Right Cessation
- 2004-06-23 AU AU2004251866A patent/AU2004251866B2/en active Active
- 2004-06-23 MX MXPA05013821A patent/MXPA05013821A/es active IP Right Grant
- 2004-06-23 NZ NZ544157A patent/NZ544157A/en not_active IP Right Cessation
- 2004-06-23 DK DK04740213T patent/DK1648934T3/da active
- 2004-06-23 US US10/560,751 patent/US20070093412A1/en not_active Abandoned
- 2004-06-23 ES ES04740213T patent/ES2328144T3/es not_active Expired - Lifetime
- 2004-06-23 BR BRPI0411820A patent/BRPI0411820B8/pt active IP Right Grant
- 2004-06-23 JP JP2006516037A patent/JP4746541B2/ja not_active Expired - Lifetime
-
2005
- 2005-12-01 IL IL172329A patent/IL172329A/en active IP Right Grant
- 2005-12-19 EC EC2005006237A patent/ECSP056237A/es unknown
- 2005-12-21 MA MA28680A patent/MA27862A1/fr unknown
- 2005-12-27 CO CO05130258A patent/CO5650225A2/es not_active Application Discontinuation
-
2006
- 2006-01-20 IS IS8247A patent/IS2705B/is unknown
- 2006-01-24 NO NO20060375A patent/NO330706B1/no unknown
- 2006-09-08 HK HK06110030.5A patent/HK1089776A1/xx not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/359,527 patent/US8299209B2/en active Active
- 2009-09-30 CY CY20091101022T patent/CY1109444T1/el unknown
- 2009-10-27 HR HR20090571T patent/HRP20090571T1/xx unknown
-
2012
- 2012-09-27 US US13/628,900 patent/US20130035286A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5650225A2 (es) | Composicion farmaceutica que comprende analogos de somatostatina ciclicos | |
| US11230568B2 (en) | Melanocortin 1 receptor ligands and methods of use | |
| McConathy et al. | Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography | |
| HRP20190966T1 (hr) | Monovalentne smjese za vezivanje sa cd28 i metode upotrebe | |
| RU2012154570A (ru) | Замещенные пиперидиновые соединения хиноксалинового типа и их применение | |
| HRP20240952T1 (hr) | Spojevi koji ciljaju psma i njihova uporaba | |
| Bridges et al. | MRP2 and the handling of mercuric ions in rats exposed acutely to inorganic and organic species of mercury | |
| Barone et al. | Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line | |
| US20240156998A1 (en) | Radiolabeled ligands for targeted pet/spect imaging and methods of their use | |
| JP2024501121A (ja) | 癌の処置 | |
| SG192544A1 (en) | Marker for determination of sensitivity to anti-cancer agent | |
| Takano et al. | Possible role of organic cation transporters in the distribution of [11C] sulpiride, a dopamine D2 receptor antagonist | |
| US6416735B1 (en) | Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine | |
| Tran et al. | Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects | |
| Deuther-Conrad et al. | Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro | |
| AR023934A1 (es) | Compuesto que consta de un derivado de benzodiacepina que se liga con un receptor iib/iiia de glicoproteina, composicion farmaceutica, agentecentellografico para la formacion de imagenes, complejo de un radionuclido emisor de y, quelado 99m tc de un compuesto que comprende una benzodiacepina, metodo | |
| JP6026499B2 (ja) | 二機能性ヒドロキシ−ビスホスホン酸誘導体 | |
| KR20160133554A (ko) | 아자인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도 | |
| HRP20100071T1 (hr) | Derivati diamino biotina i njihovi konjugati sa makrocikličnim helatirajućim sredstvima | |
| WO2008068974A1 (ja) | オーロン誘導体含有診断用組成物 | |
| KR20190139796A (ko) | Cox2 과발현 질환 진단용 조성물 및 이의 스크리닝 방법 | |
| Saito et al. | Development of novel 67/68Ga-labeled pyridyl benzofuran derivatives as islet amyloid imaging probes | |
| ES2971669T3 (es) | Separación cromatográfica de metales usando quelantes basados en DOTA | |
| EP4322961A1 (en) | Dendrimer-glutamine antagonist conjugates and methods of use thereof | |
| Wang et al. | The effects of novel macrocyclic chelates on the targeting properties of the 68Ga-labeled Gastrin releasing peptide receptor antagonist RM2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |